The Massachusetts Institute of Technology and a company that has licensed a drug patent developed at the university are suing ImClone Systems Inc., alleging that the pharmaceutical firm is using the ...

NEW YORK - A federal judge today delayed by two months the sentencing of Samuel Waksal, the former chief executive of ImClone Systems Inc.,on insider trading charges after chastising defense lawyers ...

WASHINGTON -- The former chief of embattled ImClone Systems refused to testify before Congress on Thursday about an experimental drug -- once touted as miraculous -- that cost investors millions, ...

INDIANAPOLIS — Eli Lilly & Co. has agreed to buy biotechnology company ImClone Systems Inc. for more than $6 billion in a deal that would expand Lilly’s cancer treatment pipeline a few years before ...

In the wake of mixed study results disclosed at a scientific meeting, the refusal of its partner to retool overseas research as a way of helping dislodge the FDA-stalled cancer drug Erbitux, and ...

BOSTON, June 12 (Reuters) - Repligen Corp. on Tuesday said a federal court issued the biotechnology company a favorable ruling in its patent dispute with rival ImClone Systems Inc. Repligen said the ...

Carl Icahn isn't getting his way, at least not yet. ImClone Systems responded to its most famous shareholder's latest attacks by giving him a board seat but keeping Chairman David Kies, despite ...

NEW YORK -- Clinical trial results for an experimental cancer drug, set to be released tomorrow, are expected to mark a new beginning for ImClone Systems Inc. after 18 months spent mired in scandal.

NEW YORK (CBS.MW) -- Sam Waksal pleaded guilty Tuesday to several charges related to insider trading, while prosecutors warned they may bring more charges against the former chief executive of ImClone ...

BOSTON (Reuters) - ImClone Systems Inc said on Wednesday it has received a takeover offer of $70 a share from a large pharmaceutical company, topping an earlier bid of $60 a share from Bristol-Myers ...